VC: QuatRx lands $44M in fifth round



QuatRx lands $44M in fifth round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

QuatRx
Ann Arbor, MI

$44M
Fifth

Venrock

The money is earmarked for the completion of a Phase III and Phase II study of its two endocrine programs. There's also an early-stage trial of a lipid-lowering compound.

Arete Therapeutics
Hayward, CA

$35M
First

Frazier Healthcare Ventures and Alta Partners

Arete is developing drugs for cardiovascular, inflammatory and metabolic diseases.

Biolex Therapeutics
Pittsboro, NC

$30M
Third

Investor Growth Capital

Biolex is advancing Locteron into Phase III clinical development in hepatitis C.

Intrexon
Blacksburg, VA

$25M
Third

New River Management

The money has been earmarked to fund the company's pre-clinical work in gene-based therapies.

Talima Therapeutics
Santa Clara, CA

$19M
Second

US Venture Partners and Latterell Venture Partners

The funding will allow the company to proceed through Phase II clinical trials.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.